Novavax, Inc. (NASDAQ:NVAX) Director Sells $39,008.00 in Stock

Novavax, Inc. (NASDAQ:NVAX) Director James F. Young sold 4,600 shares of the firm’s stock in a transaction that occurred on Tuesday, December 24th. The shares were sold at an average price of $8.48, for a total transaction of $39,008.00. Following the completion of the sale, the director now directly owns 57,160 shares of the company’s stock, valued at approximately $484,716.80. This represents a 7.45 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Novavax Stock Performance

NVAX opened at $8.85 on Friday. The company has a fifty day moving average price of $8.69 and a two-hundred day moving average price of $11.34. The firm has a market capitalization of $1.42 billion, a PE ratio of -3.92 and a beta of 2.07. Novavax, Inc. has a 52 week low of $3.53 and a 52 week high of $23.86.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.07. The firm had revenue of $84.51 million for the quarter, compared to the consensus estimate of $65.80 million. The company’s revenue for the quarter was down 54.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.26) earnings per share. Equities analysts forecast that Novavax, Inc. will post -1.44 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on NVAX. HC Wainwright reissued a “buy” rating and issued a $19.00 price target on shares of Novavax in a report on Tuesday, December 10th. Jefferies Financial Group lowered their target price on shares of Novavax from $31.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, October 16th. Finally, B. Riley reaffirmed a “buy” rating and set a $26.00 target price (up previously from $23.00) on shares of Novavax in a report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $17.83.

Hedge Funds Weigh In On Novavax

A number of hedge funds and other institutional investors have recently made changes to their positions in NVAX. Banque Cantonale Vaudoise boosted its position in shares of Novavax by 500.0% during the second quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 2,500 shares in the last quarter. Amalgamated Bank lifted its position in Novavax by 26.9% in the 2nd quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company’s stock valued at $62,000 after acquiring an additional 1,036 shares in the last quarter. Signaturefd LLC lifted its position in Novavax by 214.5% in the 2nd quarter. Signaturefd LLC now owns 5,680 shares of the biopharmaceutical company’s stock valued at $72,000 after acquiring an additional 3,874 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Novavax by 38.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 1,598 shares in the last quarter. Finally, Midland Wealth Advisors LLC bought a new stake in Novavax in the 2nd quarter valued at $152,000. 53.04% of the stock is owned by institutional investors.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.